ORKA · NASDAQ
Oruka Therapeutics (ORKA) Stock Price & Fundamentals
Oruka Therapeutics (ORKA) closed at $527.42 on Oct 9, 2026, up 0.99% from the previous close of $522.23.
Share price, past year
1Y +7.38%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $527.42 |
| Sep 30, 2026 | $549.23 |
| Aug 31, 2026 | $589.82 |
| Jul 31, 2026 | $575.45 |
| Jun 30, 2026 | $566.28 |
| May 29, 2026 | $566.57 |
| Apr 30, 2026 | $584.92 |
| Mar 31, 2026 | $589.27 |
| Feb 27, 2026 | $550.86 |
| Jan 30, 2026 | $528.58 |
| Dec 31, 2025 | $522.63 |
| Nov 28, 2025 | $491.60 |
| Oct 31, 2025 | $490.78 |
Key statistics
- Market cap
- $32.21B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$132.89M
- Shares outstanding
- 61.1M
- Dividend yield
- —
- 52-week range
- $472.94 – $607.35
Oruka Therapeutics's market cap is $32.21B, based on a share price of $527.42 and 61.1M shares outstanding as of Jun 30, 2026.
Financials
Oruka Therapeutics reported revenue of $0.00 for fiscal 2023.
Oruka Therapeutics reported a net loss of $105.43M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2023ended Dec 31, 2023 | $0.00 | — | −$5.34M | — | −$0.37 | −$5.01M |
| FY2022ended Dec 31, 2022 | $0.00 | — | −$9.93M | — | −$0.69 | −$10.91M |
| FY2021ended Dec 31, 2021 | $0.00 | — | −$19.32M | — | −$1.39 | −$18.81M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$9.74M | — | −$2.07 | −$7.74M |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$5.48M | — | −$4.15 | −$4.81M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$7.93M | — | −$10.31 | −$8.25M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$18.49M | — | −$1.77 | −$17.48M |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$16.44M | — | −$1.81 | — |
| FY2015ended Dec 31, 2015 | $0.00 | — | −$11.45M | — | −$1.82 | — |
| FY2014ended Dec 31, 2014 | $0.00 | — | — | — | −$3.31 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2023ended Mar 31, 2023 | $0.00 | — | −$0.09 |
| Q1 FY2022ended Mar 31, 2022 | $0.00 | — | — |
| Q1 FY2021ended Mar 31, 2021 | $0.00 | — | — |
| Q1 FY2020ended Mar 31, 2020 | $0.00 | — | — |
| Q1 FY2019ended Mar 31, 2019 | $0.00 | — | — |
| Q1 FY2018ended Mar 31, 2018 | $0.00 | — | — |
| Q1 FY2017ended Mar 31, 2017 | $0.00 | — | — |
| Q1 FY2016ended Mar 31, 2016 | $0.00 | — | — |
Company profile
- Name
- Oruka Therapeutics, Inc.
- Ticker
- ORKA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000907654
Recent SEC filings
- Aug 24, 2026
- Aug 10, 2026
- Aug 10, 2026
- Jun 4, 2026
- Jun 1, 2026
- May 13, 2026
- Apr 30, 2026
- Apr 27, 2026
Frequently asked questions
What is Oruka Therapeutics's stock price?
Oruka Therapeutics (ORKA) closed at $527.42 on Oct 9, 2026, up 0.99% from the previous close of $522.23.
What is Oruka Therapeutics's market cap?
Oruka Therapeutics's market cap is $32.21B, based on a share price of $527.42 and 61.1M shares outstanding as of Jun 30, 2026.
How much revenue does Oruka Therapeutics make?
Oruka Therapeutics reported revenue of $0.00 for fiscal 2023.
Does Oruka Therapeutics pay a dividend?
Oruka Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Oruka Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures